HSBC set a €150.00 ($174.42) price target on Sartorius (FRA:SRT3) in a research report report published on Friday, Borsen Zeitung reports. The brokerage currently has a neutral rating on the stock.
Several other research analysts have also weighed in on the stock. Deutsche Bank increased their target price on shares of Bed Bath & Beyond from $15.00 to $19.00 and gave the stock a hold rating in a research note on Thursday, April 11th. Nord/LB set a €115.00 ($133.72) price objective on shares of Sartorius and gave the company a sell rating in a research note on Tuesday, April 23rd. UBS Group set a $54.00 price objective on shares of Westlake Chemical and gave the company a sell rating in a research note on Tuesday, July 2nd. Berenberg Bank reissued a buy rating and issued a GBX 360 ($4.70) price objective on shares of in a research note on Thursday, June 6th. Finally, Hauck & Aufhaeuser set a €55.00 ($63.95) price objective on shares of Cancom and gave the company a buy rating in a research note on Thursday, April 4th. Five equities research analysts have rated the stock with a sell rating and four have issued a hold rating to the company. Sartorius presently has an average rating of Sell and an average price target of €137.94 ($160.40).
Shares of SRT3 stock opened at €184.60 ($214.65) on Friday. The stock’s 50-day moving average is €178.22. Sartorius has a 1-year low of €71.00 ($82.56) and a 1-year high of €124.70 ($145.00).
Sartorius Aktiengesellschaft supplies pharmaceutical and laboratory equipment worldwide. It operates in two divisions, Bioprocess Solutions, and Lab Products & Services. The company offers products for suspension cell analysis and live-cell analysis inside incubator for oncology, immuno-oncology, antibody discovery, neuroscience, and stem cell research; cell culture media, including antibody and recombinant protein, viral vaccines, and regenerative medicine media, as well as general media and downstream buffers; and multi-parallel, single-use, benchtop, stainless steel, microbial, and cell culture bioreactors, as well as cell culture expansion systems and software applications for bioreactors.
Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.